ROTHBLATT MARTINE A sold $5.2M of UTHR
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $543.97 ($538.34–$553.49, $5.17M total) across 14 trades on 2026-06-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CEO/Chair’s open-market sale of 9,500 shares ($5.17M) is disclosed with a stated pre-arranged 10b5-1 plan, which typically lowers the signal strength versus discretionary selling.
Market read
Traders may monitor for follow-on insider activity or interpret the sale as a sentiment check, but the 10b5-1 framing limits fundamental read-through.
What to watch
The article provides sale pricing range and post-transaction holdings, but not motivations, tax context, or whether other insiders sold/bought around the same time.
Background
The article is a SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR).
Ticker impact
United Therapeutics CEO/Chair sold $5.17M of UTHR shares via an open-market transaction under a pre-arranged 10b5-1 plan.
Likely limited immediate price impact; any effect is more sentiment/positioning than fundamentals.
The filing is a primary Form 4 disclosure with transaction size and pricing, but the presence of a 10b5-1 plan reduces interpretability as a new negative signal.
Market effects
Minimal; this is company-specific insider activity with no sector-wide catalyst described.
None indicated.
None indicated.
Counterpoint
Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than a change in outlook.
Key entities
- issuerUNITED THERAPEUTICS Corp
Company whose shares were sold by its CEO/Chairperson.
- insiderROTHBLATT MARTINE A
Chairperson & CEO who sold shares under a 10b5-1 plan.
